Company Shares of Biogen (NASDAQ:BIIB) Rally 2.55%

Biogen (NASDAQ:BIIB) : Traders are bullish on Biogen (NASDAQ:BIIB) as it has outperformed the S&P 500 by a wide margin of 0.48% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.25%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.55% in the last 1 week, and is up 2.1% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -35.77% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $412.24 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $254.14 and the 200 Day Moving Average price is recorded at $265.29.

The stock has recorded a 20-day Moving Average of 4.92% and the 50-Day Moving Average is 2.99%.


Biogen (NASDAQ:BIIB): stock turned positive on Friday. Though the stock opened at $248.63, the bulls momentum made the stock top out at $251.78 level for the day. The stock recorded a low of $246.11 and closed the trading day at $251.3, in the green by 1.63%. The total traded volume for the day was 1,296,446. The stock had closed at $247.27 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Koppel Adam, officer (EVP, Strategy and Bus. Dev.) of Biogen Inc., had unloaded 555 shares at an average price of $290 in a transaction dated on June 6, 2016. The total value of the transaction was worth $160,950.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *